Adaptimmune Therapeutics plc
Income Statement
| Line Item | FY2016 | FY2015 | FY2014 |
|---|---|---|---|
| Revenue | $14.2M | $9.9M | $825.0K |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $63.8M | $24.1M | $9.6M |
| SG&A Expense | $23.2M | $10.4M | $2.8M |
| Operating Income | $-72.8M | $-24.6M | $-11.5M |
| Operating Margin | -512.7% | -249.6% | -1,396.5% |
| Interest Expense | — | — | — |
| Pretax Income | $-70.7M | $-21.8M | $-11.5M |
| Income Tax Expense | $892.0K | $244.0K | $75.0K |
| Net Income | $-71.6M | $-22.1M | $-11.6M |
| Net Margin | -504.1% | -223.5% | -1,406.2% |
| EPS (Basic) | $-0.17 | $-0.17 | $-0.08 |
| EPS (Diluted) | $-0.17 | $-0.17 | $-0.08 |
| Shares Outstanding (Basic) | 424.8M | 424.7M | — |
| Shares Outstanding (Diluted) | 424.8M | 424.7M | — |
| Dividends Per Share | — | — | — |